DK3658140T3 - Kombinationer af aprocitentan med yderligere aktive bestanddele til behandlingen af resistent hypertension - Google Patents

Kombinationer af aprocitentan med yderligere aktive bestanddele til behandlingen af resistent hypertension

Info

Publication number
DK3658140T3
DK3658140T3 DK17794712.4T DK17794712T DK3658140T3 DK 3658140 T3 DK3658140 T3 DK 3658140T3 DK 17794712 T DK17794712 T DK 17794712T DK 3658140 T3 DK3658140 T3 DK 3658140T3
Authority
DK
Denmark
Prior art keywords
aprocitentan
combinations
treatment
active ingredients
additional active
Prior art date
Application number
DK17794712.4T
Other languages
Danish (da)
English (en)
Inventor
Marc Bellet
Martin Bolli
Martine Clozel
Marc Iglarz
Philipp Kohler
Ivan Schindelholz
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60268369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3658140(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3658140T3 publication Critical patent/DK3658140T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
DK17794712.4T 2017-02-27 2017-11-06 Kombinationer af aprocitentan med yderligere aktive bestanddele til behandlingen af resistent hypertension DK3658140T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017054489 2017-02-27
EP2017061487 2017-05-12
PCT/EP2017/078371 WO2018153513A1 (en) 2017-02-27 2017-11-06 Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

Publications (1)

Publication Number Publication Date
DK3658140T3 true DK3658140T3 (da) 2025-08-25

Family

ID=60268369

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17794712.4T DK3658140T3 (da) 2017-02-27 2017-11-06 Kombinationer af aprocitentan med yderligere aktive bestanddele til behandlingen af resistent hypertension
DK21202979.7T DK4014976T3 (da) 2017-02-27 2018-02-26 Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21202979.7T DK4014976T3 (da) 2017-02-27 2018-02-26 Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan

Country Status (28)

Country Link
US (5) US11174247B2 (OSRAM)
EP (3) EP3658140B1 (OSRAM)
JP (3) JP7223701B2 (OSRAM)
KR (3) KR102568472B1 (OSRAM)
CN (3) CN110325186A (OSRAM)
AU (2) AU2017400276B2 (OSRAM)
BR (2) BR112019017658A2 (OSRAM)
CA (2) CA3053991A1 (OSRAM)
CL (3) CL2019002464A1 (OSRAM)
DK (2) DK3658140T3 (OSRAM)
ES (2) ES3038007T3 (OSRAM)
FI (2) FI3658140T3 (OSRAM)
HR (2) HRP20250921T1 (OSRAM)
HU (2) HUE072288T2 (OSRAM)
IL (4) IL315563A (OSRAM)
LT (2) LT3658140T (OSRAM)
MA (2) MA49664A (OSRAM)
MX (3) MX392313B (OSRAM)
MY (2) MY199557A (OSRAM)
PH (2) PH12019501937A1 (OSRAM)
PL (2) PL3658140T3 (OSRAM)
PT (2) PT3658140T (OSRAM)
RS (2) RS67082B1 (OSRAM)
SG (3) SG11201907435PA (OSRAM)
SI (2) SI3658140T1 (OSRAM)
TW (2) TWI786089B (OSRAM)
UA (1) UA126122C2 (OSRAM)
WO (2) WO2018153513A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958110A1 (en) * 2014-08-14 2016-02-18 Vivus, Inc. Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
EP3658140B1 (en) 2017-02-27 2025-05-21 Idorsia Pharmaceuticals Ltd Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension
MY210547A (en) * 2017-11-30 2025-09-30 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
JP7312262B2 (ja) 2018-09-28 2023-07-20 フロー メディカル コーポレイション カテーテル装置
SMT202400274T1 (it) * 2018-12-21 2024-09-16 Actelion Pharmaceuticals Ltd Macitentan per il trattamento di ipertensione arteriosa polmonare
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CN112569357B (zh) * 2019-09-30 2023-03-28 深圳奥萨制药有限公司 双重内皮素受体拮抗剂与利尿剂的组合物
CN112679441A (zh) * 2019-10-18 2021-04-20 普济生物科技（台州）有限公司 阿普昔腾坦的晶型、制备方法及其用途
CN114630668B (zh) * 2019-11-07 2024-02-27 苏州科睿思制药有限公司 一种Aprocitentan晶型及其制备方法和用途
WO2021237004A1 (en) 2020-05-21 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of aprocitentan and process for preparation thereof
CR20230083A (es) 2020-07-10 2023-05-16 Astrazeneca Ab Combinación de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal crónica
CN114644595A (zh) * 2020-12-19 2022-06-21 普济生物科技（台州）有限公司 阿普昔腾坦的无定型态、其药物组合物和用途
WO2023111797A1 (en) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Pyrimidine sulfamide derivatives and process for manufacturing them
JP2025519101A (ja) 2022-05-22 2025-06-24 イドルシア・ファーマシューティカルズ・リミテッド 高血圧の治療のための４－ピリミジンスルファミド誘導体の使用
AU2023275935A1 (en) 2022-05-25 2025-01-09 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
WO2024140425A1 (zh) * 2022-12-30 2024-07-04 苏州科睿思制药有限公司 一种阿普昔腾坦晶型及其制备方法和用途
KR20250152723A (ko) 2024-04-16 2025-10-24 경북대학교 산학협력단 신규한 피리미딘 유도체 화합물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569116A (en) 1896-10-06 Washlngtorf
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
WO2002053557A1 (en) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
AU2007217100A1 (en) 2006-02-17 2007-08-30 Gilead Colorado, Inc. Antihypertensive therapy
US20070293552A1 (en) 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
AR061627A1 (es) 2006-06-27 2008-09-10 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
MX2010001837A (es) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
EP2545920A1 (en) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
DK3222277T3 (da) 2009-03-31 2020-05-11 Ligand Pharm Inc Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati
CN102614189B (zh) * 2012-04-17 2014-10-22 北京哈三联科技股份有限公司 含缬沙坦、氨氯地平和氢氯噻嗪的微丸药物组合
EP2907811A1 (en) 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
CN107106522A (zh) 2014-11-07 2017-08-29 艾伯维公司 使用液体潴留的预测因子治疗ckd的方法
WO2017185142A1 (en) 2016-04-29 2017-11-02 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating atrial fibrillation
EP3658140B1 (en) 2017-02-27 2025-05-21 Idorsia Pharmaceuticals Ltd Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension
MY210547A (en) 2017-11-30 2025-09-30 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
SMT202400274T1 (it) * 2018-12-21 2024-09-16 Actelion Pharmaceuticals Ltd Macitentan per il trattamento di ipertensione arteriosa polmonare

Also Published As

Publication number Publication date
US20200002317A1 (en) 2020-01-02
CA3053994A1 (en) 2018-08-30
KR102577375B1 (ko) 2023-09-11
US10919881B2 (en) 2021-02-16
JP2020508338A (ja) 2020-03-19
US20230391757A1 (en) 2023-12-07
PH12019501938A1 (en) 2020-07-06
WO2018154101A1 (en) 2018-08-30
TW201835071A (zh) 2018-10-01
IL268850B2 (en) 2025-02-01
SI4014976T1 (sl) 2025-01-31
US20200061061A1 (en) 2020-02-27
MY208610A (en) 2025-05-20
AU2018225309A1 (en) 2019-10-17
JP7223701B2 (ja) 2023-02-16
TWI854353B (zh) 2024-09-01
IL297993B2 (en) 2025-04-01
RS67082B1 (sr) 2025-09-30
US11680058B2 (en) 2023-06-20
UA126122C2 (uk) 2022-08-17
LT4014976T (lt) 2024-11-11
US11787782B2 (en) 2023-10-17
RS66200B1 (sr) 2024-12-31
SG10202111695RA (en) 2021-12-30
ES3006308T3 (en) 2025-03-18
IL297993B1 (en) 2024-12-01
KR20190119635A (ko) 2019-10-22
IL268850B1 (en) 2024-10-01
US20220064149A1 (en) 2022-03-03
ES3038007T3 (en) 2025-10-08
PL3658140T3 (pl) 2025-09-08
AU2018225309B2 (en) 2024-01-18
SI3658140T1 (sl) 2025-08-29
US20210206750A1 (en) 2021-07-08
HUE072288T2 (hu) 2025-11-28
MX2021007184A (es) 2021-07-21
NZ757344A (en) 2025-10-31
BR112019017658A2 (pt) 2020-03-31
MA47596A (fr) 2021-05-05
PT4014976T (pt) 2024-12-04
SG11201907435PA (en) 2019-09-27
US12297189B2 (en) 2025-05-13
SG11201907604UA (en) 2019-09-27
MX392313B (es) 2025-03-21
MX2019010222A (es) 2019-10-24
CA3053991A1 (en) 2018-08-30
KR20190121827A (ko) 2019-10-28
PL4014976T3 (pl) 2024-12-23
IL297993A (en) 2023-01-01
CL2020001762A1 (es) 2020-11-20
JP2020508339A (ja) 2020-03-19
HRP20241461T1 (hr) 2025-01-03
EP3585391A1 (en) 2020-01-01
HUE069231T2 (hu) 2025-02-28
KR20230074610A (ko) 2023-05-30
TW202330502A (zh) 2023-08-01
EP3658140B1 (en) 2025-05-21
WO2018153513A1 (en) 2018-08-30
KR102700778B1 (ko) 2024-08-29
JP7520951B2 (ja) 2024-07-23
CL2019002470A1 (es) 2020-02-21
IL315563A (en) 2024-11-01
HRP20250921T1 (hr) 2025-09-26
CN117946011A (zh) 2024-04-30
AU2017400276B2 (en) 2024-01-11
CN110381948A (zh) 2019-10-25
BR112019017644A2 (pt) 2020-03-31
FI4014976T3 (fi) 2024-11-05
EP4014976B1 (en) 2024-09-04
MX2019010221A (es) 2019-10-21
MY199557A (en) 2023-11-07
EP3658140A1 (en) 2020-06-03
LT3658140T (lt) 2025-08-25
CL2019002464A1 (es) 2020-01-31
TWI786089B (zh) 2022-12-11
PH12019501937A1 (en) 2020-07-06
US11174247B2 (en) 2021-11-16
CN110325186A (zh) 2019-10-11
PT3658140T (pt) 2025-08-19
JP2023027305A (ja) 2023-03-01
IL268850A (en) 2019-10-31
KR102568472B1 (ko) 2023-08-18
EP4014976A1 (en) 2022-06-22
AU2017400276A1 (en) 2019-10-17
MA49664A (fr) 2020-06-03
IL268852A (en) 2019-10-31
DK4014976T3 (da) 2024-12-02
FI3658140T3 (fi) 2025-08-12

Similar Documents

Publication Publication Date Title
PL3658140T3 (pl) Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
DK3501542T3 (da) Esketamin til behandling af depression
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3658539T3 (da) Forbindelser og sammensætninger til behandling af tilstande, som er forbundet med nlrp-aktivitet
DK3612215T3 (da) Sammensætninger til behandling af lungeinflammation
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
EP3606482A4 (en) PRODUCTION OF A COLD THICK SUSPENSION AT THE POINT OF ADMINISTRATION
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3805220T3 (da) Polycykliske carbamoylpyridon-derivater til behandling af hiv
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK4101454T3 (da) Sammensætninger til behandling af hypertension
DK3612208T5 (da) Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
DK3833746T5 (da) Mini-gde til behandlingen af glykogenlagringssygdom iii
DK3506901T3 (da) Anvendelse af kynurensyre til behandling af muskelatrofi
DK3618845T3 (da) Peptider til behandling af diabetes
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler
DK3283064T3 (da) Derivater til anvendelse i behandling af muskelatrofi